Martin Jönsson

Chairman & CEO

C-suiteM

FI·FIN-FSA

AlzeCure Pharma AB AlzeCure Pharma AB Nordnet AB (publ)Nordnet AB (publ)

Cumul. flow

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Browse the detailed record of transactions filed by Martin Jönsson, Chairman & CEO. Director active across 4 companies, notably AlzeCure Pharma AB. Cumulatively, 3 disclosures have been published. The latest transaction was disclosed on 6 March 2026 — Purchase. Regulator: FIN-FSA. The full history is free.

Declarations3 total

Executives●PurchaseNNordnet AB (publ)13FIN-FSA

M

Martin JönssonStyrelseledamot

€2,6125,000 shares@ €0.52250.0000% mcap19.8% of flow

Aktie

FI:A003W808-1·6 Mar 2026

Ideal exit: 1 Dec 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseNNordnet AB (publ)19FIN-FSA

M

Martin JönssonStyrelseledamot

€10,56519,800 shares@ €0.53360.0000% mcap80.2% of flow

Aktie

FI:A003W633-1·2 Mar 2026

Ideal exit: 27 Nov 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseAAlzeCure Pharma AB35FIN-FSA

M

Martin JönssonVerkställande direktör (VD)

€1,5858,067 shares@ €0.19650.0010% mcap100.0% of flow

Aktie

FI:A003R766-1·25 Aug 2025

Ideal exit: 22 May 2026 (T+270)

FIN-FSA ↗

3 of 3 declarations

About Martin Jönsson

Martin Jönsson is the CEO of AlzeCure Pharma AB. He leads the company in developing new therapies for neurodegenerative diseases. With a strong background in the pharmaceutical sector, he is committed to advancing research projects and strengthening AlzeCure's market position. Under his leadership, the company has focused on innovation and collaboration with other industry players.